Skip to main content

FDA Approvals

Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology

Lisa A. Raedler, PhD, RPh

Adverse Events Reporting in Oncology Studies Suboptimal

Ibrutinib Approved for Chronic Lymphocytic Leukemia

Tafinlar Receives Breakthrough Therapy Designation for Lung Cancer

Brintellix (Vortioxetine) Receives FDA Approval for the Treatment of Major Depressive Disorder

Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia

Fetzima Extended-Release Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults

Simponi Aria: A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Page 45 of 53
Results 441 - 450 of 522